User profiles for Alvaro Arjona Sánchez
 | Alvaro Arjona-SanchezSurgeon PhD Verified email at juntadeandalucia.es Cited by 1629 |
Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial
A Arjona-Sánchez, E Espinosa-Redondo… - JAMA …, 2023 - jamanetwork.com
Importance Peritoneal metastasis in patients with locally advanced colon cancer (T4 stage)
is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is …
is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is …
[HTML][HTML] Colorectal peritoneal metastases: Optimal management review
…, L Rodríguez-Ortiz, Á Arjona-Sánchez… - World journal of …, 2019 - ncbi.nlm.nih.gov
The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer
prognosis than other sites of metastases. In the last two decades, it has been considered as a …
prognosis than other sites of metastases. In the last two decades, it has been considered as a …
[HTML][HTML] Gastrointestinal stromal tumors: a multidisciplinary challenge
…, S Rufian-Peña, A Arjona-Sanchez… - World journal of …, 2018 - ncbi.nlm.nih.gov
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors located
in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small …
in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small …
[HTML][HTML] HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used …
A Arjona-Sánchez, P Barrios, E Boldo-Roda, B Camps… - BMC cancer, 2018 - Springer
Background Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated
in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, …
in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, …
[HTML][HTML] Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring
novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is …
novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is …
[HTML][HTML] GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after …
…, L González-Bayón, A Arjona-Sánchez… - BMC cancer, 2022 - Springer
Background The French PRODIGE 7 trial, published on January 2021, has raised doubts
about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m 2 (30 minutes) …
about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m 2 (30 minutes) …
[HTML][HTML] Conservative management of perforated duodenal diverticulum: a case report and review of the literature
D Martínez-Cecilia, A Arjona-Sánchez… - World journal of …, 2008 - ncbi.nlm.nih.gov
Duodenal diverticula are a relatively common condition. They are asymptomatic, unless
they become complicated, with perforation being the rarest but most severe complication. …
they become complicated, with perforation being the rarest but most severe complication. …
A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei
Á Arjona-Sánchez, A Martínez-López… - Annals of Surgical …, 2022 - Springer
Background Pseudomyxoma peritonei (PMP) is a rare malignancy, classified according to
the Peritoneal Surface Oncology Group International (PSOGI) classification, whose response …
the Peritoneal Surface Oncology Group International (PSOGI) classification, whose response …
[HTML][HTML] Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview
A Arjona-Sánchez, FJ Medina-Fernández… - World journal of …, 2014 - ncbi.nlm.nih.gov
Colorectal peritoneal carcinomatosis was considered a terminal condition with a merely
palliative treatment that included only supportive care, palliative surgery and the best systemic …
palliative treatment that included only supportive care, palliative surgery and the best systemic …
[HTML][HTML] Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: an international multicentre cohort study
VP Bastiaenen, AGJ Aalbers, A Arjona-Sánchez… - European Journal of …, 2021 - Elsevier
Introduction With evolving treatment strategies aiming at prevention or early detection of
metachronous peritoneal metastases (PM), identification of high-risk colon cancer patients …
metachronous peritoneal metastases (PM), identification of high-risk colon cancer patients …